Pharmaceuticals News

Press Releases from Pharmaceuticals Companies

Newsroom

Pharmaceuticals news releases from pharmaceuticals companies published by Newsfile. Searches will return results from stories up to two years old.

Beyond Medical Technologies Announces Corporate Name Change to Republic Technologies
Vancouver, British Columbia--(Newsfile Corp. - July 16, 2025) - Beyond Medical Technologies Inc. (CSE: DOCT) (FSE: 7FM) (the "Company") is pleased to announce that it has changed its name to Republic Technologies Inc. ("Republic"), effective on July 15th, 2025.The new CUSIP for the Company's common shares will be 760801100 and...
Technology, Pharmaceuticals, Health
2025-07-16 12:21 AM EDT | Republic Technologies Inc.
Defence's Accum Technology with ADC and Radiopharmaceutical Programs Target Cancer
Montreal, Quebec--(Newsfile Corp. - July 14, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug delivery technologies, is pleased to announce that its highly impactful programs on ADC and Radiopharma programs, which includes collaborations and preclinical studies on cancer...
Biotechnology, Pharmaceuticals, Health
2025-07-14 3:15 AM EDT | Defence Therapeutics Inc.
SOL Global Provides Update on Portfolio Company McQueen Labs
Toronto, Ontario--(Newsfile Corp. - July 10, 2025) - SOL Global Investments Corp. (CSE: SOL) (FSE: 9SB) ("SOL Global" or the "Company"), one of the first publicly traded companies focused on institutional Solana investments, is pleased to provide an update regarding the ongoing developments at its portfolio company, McQueen Labs Inc....
Healthcare and Hospitals, Pharmaceuticals
2025-07-10 8:00 AM EDT | SOL Global Investments Corp.
Hemostemix Oversubscribed, Closing $2,700,000 Private Placement and Settles $400,000 of Debt at $0.20 per Share
Calgary, Alberta--(Newsfile Corp. - July 9, 2025) - Hemostemix Inc's (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") non brokered private placement of $2,500,000 announced June 26 is oversubscribed. The Company will close the first tranche of $ 2,700,000, subject to the TSX Venture Exchange ("TSXV") approval on...
Biotechnology, Pharmaceuticals, Health
2025-07-09 11:00 AM EDT | Hemostemix Inc.
PreveCeutical Announces Rescheduled Date for Annual General and Special Meeting
Vancouver, British Columbia--(Newsfile Corp. - July 9, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that, further to its News Release of June 25, 2025, it has rescheduled its annual general and special meeting from August 15, 2025 to September 5, 2025 at which...
Biotechnology, Pharmaceuticals, Health
2025-07-09 7:00 AM EDT | PreveCeutical Medical Inc.
NervGen Provides Quarterly "At-The-Market" Equity Program and Grant of Options Update
Vancouver, British Columbia--(Newsfile Corp. - July 7, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biotech company dedicated to developing innovative treatments for spinal cord injury (SCI) and other neurological conditions, today provided a quarterly update with respect to the Company's previously announced at-the-market equity...
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-07-07 5:30 PM EDT | NervGen Pharma Corp.
InsuJet Distribution Expands Across France
Toronto, Ontario--(Newsfile Corp. - July 7, 2025) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen" or the "Company"), a leader in needle-free subcutaneous drug-delivery technology, today unveiled www.insujet.fr — a dedicated French-language information and e-commerce site for InsuJet™, the Company's needle-free insulin-delivery device.Developed with NuGen's exclusive d
Healthcare and Hospitals, Pharmaceuticals, Health
2025-07-07 5:15 PM EDT | NuGen Medical Devices Inc.
Hemostemix Closes $469,366 Private Placement
Calgary, Alberta--(Newsfile Corp. - July 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces that the TSX Venture Exchange ("TSXV") conditionally approved the Company's previously disclosed non-brokered private placement (the "Offering") in the amount of CAD $469,366. The Offering consisted of the issuance...
Biotechnology, Pharmaceuticals, Health
2025-07-04 8:20 AM EDT | Hemostemix Inc.
NervGen Strengthens Board Leadership to Accelerate Clinical and Corporate Growth
Dr. Adam Rogers appointed chair as company advances toward key milestones following positive topline chronic cohort results of Phase 1b/2a CONNECT SCI StudyVancouver, British Columbia--(Newsfile Corp. - July 3, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative treatments for spinal...
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-07-03 4:41 PM EDT | NervGen Pharma Corp.
Hemostemix Announces its 10th Publication: A Molecular Strategy for the Treatment of Heart Failure: Response to BioCardia's Cardiamp Heart Failure Trial
Calgary, Alberta--(Newsfile Corp. - July 3, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is proud to share the Journal of Biomedical Research and Environmental Science published Autologous Angiogenic Cell Precursors-A Molecular Strategy for The Treatment of Heart Failure: Response to BioCardia's Cardiamp HF Trial.Recent research has revealed the...
Biotechnology, Pharmaceuticals, Health
2025-07-03 10:16 AM EDT | Hemostemix Inc.
Hemostemix's VesCell Sales are Legal in Florida as it Pivots to Allow Non-FDA Approved Stem Cell Treatments!
Calgary, Alberta--(Newsfile Corp. - July 2, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), a clinical-stage biotechnology company focused on autologous stem cell therapies for cardiovascular diseases, is pleased to announce that Florida Senate Bill 1768 has officially become law on July 1, which enables the commercial...
Biotechnology, Pharmaceuticals, Health
2025-07-02 3:00 AM EDT | Hemostemix Inc.
Movora and dvmGRO Partner to Enhance Veterinary Surgery, Orthopedics and Continuing Education
Charleston, South Carolina--(Newsfile Corp. - July 1, 2025) - dvmGRO, a leading veterinary network dedicated to elevating practice success, is proud to announce a strategic partnership with Movora, a global leader in veterinary orthopedic and surgical solutions. Effective July 1, 2025, this collaboration brings expanded benefits and resources to veterinary...
Healthcare and Hospitals, Pharmaceuticals, Health
2025-07-01 9:00 AM EDT | Movora
NervGen Announces Clinical Leadership Transition as NVG-291 Continues to Advance Toward Late-Stage Development and Regulatory Milestones
Vancouver, British Columbia--(Newsfile Corp. - July 1, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neuroreparative therapeutics, today announced that Daniel Mikol, MD, Ph.D., has resigned from his position as Chief Medical Officer in order to pursue new opportunities. Randall Kaye, MD,...
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-07-01 7:30 AM EDT | NervGen Pharma Corp.
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2025 and Provides Conference Call Information
Northvale, New Jersey--(Newsfile Corp. - June 30, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the fiscal year ended March 31, 2025 ("Fiscal 2025").Consolidated revenues for Fiscal 2025 were $84.0 million, an increase of $27.4 million or approximately...
Healthcare and Hospitals, Pharmaceuticals, Health
2025-06-30 4:13 PM EDT | Elite Pharmaceuticals, Inc.
Flora Growth Announces Results of 2025 Annual and Special Meeting of Shareholders
Fort Lauderdale, Florida--(Newsfile Corp. - June 30, 2025) - Flora Growth Corp. (NASDAQ: FLGC) (FSE: 7301) ("Flora" or the "Company") held its 2025 Annual and Special Meeting of Shareholders (the "Annual Meeting"). The final voting results of the proposals submitted to a vote of the Company's shareholders at the Annual...
Pharmaceuticals, Cannabis, Cannabis Cultivator, Cannabis Manufacturer
2025-06-30 2:01 PM EDT | Flora Growth Corp.
PreveCeutical Welcomes Dr. Francis Tavares, PhD. As Chief Technology Officer
Vancouver, British Columbia--(Newsfile Corp. - June 30, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to have appointed Dr. Francis Tavares as a corporate advisor...
Biotechnology, Pharmaceuticals, Health
2025-06-30 11:53 AM EDT | PreveCeutical Medical Inc.
Theralase(R) Extends Warrants
Toronto, Ontario--(Newsfile Corp. - June 27, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, is pleased to announce that the Company proposes to extend the...
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2025-06-27 4:30 PM EDT | Theralase Technologies Inc.
Croom Lawrence Joins Hemostemix with Revenue Share Agreement and VesCell.Health Launch
Calgary, Alberta--(Newsfile Corp. - June 27, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF), a leading Phase III autologous stem cell therapy company and Mr. Croom Lawrence are pleased to announce Croom has joined Hemostemix as its Chief Commercialization Officer, and partnered to offer MCI Screen through Hemostemix. MCI Screen...
Biotechnology, Pharmaceuticals, Health
2025-06-27 11:54 AM EDT | Hemostemix Inc.
Beyond Medical Technologies Reports Robust H1 2025 Progress, Sets Stage for Republic Technologies
Vancouver, British Columbia--(Newsfile Corp. - June 27, 2025) - Beyond Medical Technologies Inc. (CSE: DOCT) (FSE: 7FM) (OTC Pink: DOCKF) ("Beyond Medical" or the "Company") is pleased to report progress in the first half of 2025, highlighting strategic achievements that support its transformation into Republic Technologies Inc., which is positioned...
Technology, Pharmaceuticals, Health
2025-06-27 9:00 AM EDT | Republic Technologies Inc.
InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules
Vancouver, British Columbia--(Newsfile Corp. - June 27, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the closing of its previously announced private placement priced at-the-market under...
Biotechnology, Pharmaceuticals
2025-06-27 7:00 AM EDT | InMed Pharmaceuticals

Have you heard? TMX Group has acquired Newsfile

Pharmaceuticals News

Press Releases from Pharmaceuticals Companies

Newsroom

RSS Feeds

Tell your pharmaceuticals story, report your results

Cookie Settings

Have you heard? TMX Group has acquired Newsfile

Tell your pharmaceuticals story, report your results